94 related articles for article (PubMed ID: 26860337)
1. Survival of breast cancer patients according to changes in expression of selected markers between primary tumor and lymph node metastases.
Adamczyk A; Niemiec J; Ambicka A; Mucha-Małecka A; Ryś J; Mituś J; Wysocki WM; Cichocka A; Jakubowicz J
Biomark Med; 2016; 10(3):219-28. PubMed ID: 26860337
[TBL] [Abstract][Full Text] [Related]
2. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
3. Expression of ER/PR/HER2, basal markers and adhesion molecules in primary breast cancer and in lymph nodes metastases: a comparative immunohistochemical analysis.
Adamczyk A; Niemiec J; Ambicka A; Małecki K; Wysocki WH; Mituś J; Ryś J
Pol J Pathol; 2012 Dec; 63(4):228-34. PubMed ID: 23359191
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients.
Kwon Y; Ro J; Kang HS; Kim SK; Hong EK; Khang SK; Gong G; Ro JY
Oncol Rep; 2011 Apr; 25(4):1063-71. PubMed ID: 21258771
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of e-cadherin in primary breast cancer and corresponding lymph node metastases.
Fulga V; Rudico L; Balica AR; Cimpean AM; Saptefrati L; Margan MM; Raica M
Anticancer Res; 2015 Feb; 35(2):759-65. PubMed ID: 25667455
[TBL] [Abstract][Full Text] [Related]
7. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
[TBL] [Abstract][Full Text] [Related]
8. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients.
van den Hoven I; van Klaveren D; Voogd AC; Vergouwe Y; Tjan-Heijnen V; Roumen RM
Clin Breast Cancer; 2016 Apr; 16(2):123-30. PubMed ID: 26602438
[TBL] [Abstract][Full Text] [Related]
9. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer.
Harigopal M; Berger AJ; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2005 Jun; 11(11):4083-9. PubMed ID: 15930343
[TBL] [Abstract][Full Text] [Related]
10. Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion.
Milioli HH; Santos Sousa K; Kaviski R; Dos Santos Oliveira NC; De Andrade Urban C; De Lima RS; Cavalli IJ; De Souza Fonseca Ribeiro EM
Cancer Genomics Proteomics; 2015; 12(2):89-101. PubMed ID: 25770193
[TBL] [Abstract][Full Text] [Related]
11. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
13. BGX-Ki-67 index as a supplementary marker to MIB-1 index, enabling more precise distinction between luminal A and B subtypes of breast carcinoma and eliminating the problem of membranous/cytoplasmic MIB-1 staining.
Niemiec J; Adamczyk A; Ambicka A; Mucha-Małecka A; Wysocki WM; Majchrzyk K; Ryś J
Am J Clin Pathol; 2015 Mar; 143(3):419-29. PubMed ID: 25696801
[TBL] [Abstract][Full Text] [Related]
14. Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.
Nogi H; Suzuki M; Kamio M; Kato K; Kawase K; Toriumi Y; Takeyama H; Fukushima H; Morikawa T; Uchida K
Oncol Rep; 2011 Apr; 25(4):1109-15. PubMed ID: 21308353
[TBL] [Abstract][Full Text] [Related]
15. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
17. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of metastatic behaviour of breast cancer subtypes.
Savci-Heijink CD; Halfwerk H; Hooijer GK; Horlings HM; Wesseling J; van de Vijver MJ
Breast Cancer Res Treat; 2015 Apr; 150(3):547-57. PubMed ID: 25820592
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
